{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-119551","form_type":"8-K","ticker":"APRE","cik":"0001781983","company_name":"Aprea Therapeutics, Inc.","filed_at":"2022-11-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.092875+00:00","generated_at":"2026-06-21T17:39:21.508980+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Aprea Therapeutics regains compliance with Nasdaq minimum $10M stockholders' equity requirement","bullets":["Received deficiency letter on Aug 15, 2022 for failing minimum $10M stockholders' equity rule.","Based on Q3 2022 10-Q showing equity of ~$26.6M, Nasdaq confirmed compliance regained.","Listing on Nasdaq Global Select Market continues without risk of delisting."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-119551","json":"https://secwatch.observer/filing/0001104659-22-119551.json","markdown":"https://secwatch.observer/filing/0001104659-22-119551.md","text":"https://secwatch.observer/filing/0001104659-22-119551.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1781983/000110465922119551/0001104659-22-119551-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1781983/000110465922119551/tm2230665d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T17:39:21.508980+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6fb8ec60f621f8c9daecac23c9c27fea936f55bc","claim":"Aprea Therapeutics, Inc. received a nasdaq compliance regained notice regarding stockholders equity (rules 5450(b)(1)(A)).","evidence_excerpt":"set forth in Listing Rule 5450(b)(1)(A) (the “Rule”). Based on the Company’s Form 10-Q for the period ended September 30, 2022, evidencing stockholders’ equity of approximately $26.6 million, the Staff has determined that the Company has regained compliance with the Rule. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1781983/000110465922119551/0001104659-22-119551-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"compliance regained"},{"label":"Deficiency","value":"stockholders equity"},{"label":"Rules","value":"5450(b)(1)(A)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}